Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea.
J Neurogastroenterol Motil. 2010 Apr;16(2):177-85. doi: 10.5056/jnm.2010.16.2.177. Epub 2010 Apr 27.
BACKGROUND/AIMS: There has been a controversy regarding the usefulness of biofeedback therapy for functional constipation or fecal incontinence. This study was performed to investigate the long-term clinical efficacy of biofeedback therapy.
Sixty-four patients with constipation or fecal incontinence received biofeedback therapy for 4 weeks. Symptom improvements were evaluated immediately after the completion of biofeedback therapy and during the follow-up period of about 12 to 64 months.
Twenty-five patients in the constipation group [mean age of 52.1 years, 16 men (64.0%)] received 6.2 sessions of biofeedback therapy. Improvement of constipation after the completion of biofeedback therapy was as follows: major response (or improvement) in 3 patients (12.0%), fair in 6 (24.0%), minor in 11 (44.0%) and none in 5 (20.0%). Among 9 patients who showed major or fair improvement, 8 patients (88.9%) maintained the symptom improvement through the long term follow-up periods. Thirty-nine patients in the fecal incontinence group [59.7 years old, 15 men (38.5%)] received 6.8 sessions of biofeedback therapy. Improvement of incontinence after the completion of biofeedback therapy was as follows: major improvement in 6 patients (15.4%), fair in 14 (35.9%), minor in 14 (35.9%), and none in 5 (12.8%). All 11 patients with major or fair improvement maintained the symptom improvement to the end of follow-up periods.
Symptom improvements after biofeedback therapy were disappointing in both the constipation and incontinence group. However, when the symptom improvements were classified as major or fair, the improvements continued for at least a year.
背景/目的:生物反馈疗法对于功能性便秘或粪便失禁的有效性一直存在争议。本研究旨在调查生物反馈疗法的长期临床疗效。
64 例便秘或粪便失禁患者接受生物反馈治疗 4 周。在完成生物反馈治疗后和大约 12 至 64 个月的随访期间,立即评估症状改善情况。
便秘组 25 例患者(平均年龄 52.1 岁,16 名男性[64.0%])接受了 6.2 次生物反馈治疗。完成生物反馈治疗后便秘的改善情况如下:3 例(12.0%)有主要反应(或改善),6 例(24.0%)有良好反应,11 例(44.0%)有轻度改善,5 例(20.0%)无改善。在 9 例有明显或改善的患者中,8 例(88.9%)在长期随访期间保持了症状改善。粪便失禁组 39 例患者(59.7 岁,15 名男性[38.5%])接受了 6.8 次生物反馈治疗。完成生物反馈治疗后失禁的改善情况如下:6 例(15.4%)有明显改善,14 例(35.9%)有良好改善,14 例(35.9%)有轻度改善,5 例(12.8%)无改善。所有 11 例有明显或改善的患者在随访结束时均保持症状改善。
生物反馈治疗后便秘和失禁组的症状改善均不令人满意。然而,当症状改善被分类为明显或改善时,改善至少持续了一年。